Odonate Company Description

Odonate, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer.

It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with metastatic breast cancer.

The company was formerly known as Odonate Therapeutics, Inc. and changed its name to Odonate, Inc. in March 2023.

The company was founded in 2013 and is based in New York, New York.

Odonate, Inc.

Country	United States
Founded	2013
Industry	Biotechnology
Sector	Healthcare
Employees	145
CEO	Kevin Tang

Contact Details

Address: 3 East 28th Street New York, Delaware 10016 United States
Phone	332 206 0935
Website	odonate.com

Stock Details

Ticker Symbol	ODTC
Exchange	OTCMKTS
Fiscal Year	January - December
Reporting Currency	USD
ISIN Number	US6760792050
SIC Code	9995

Key Executives

Name	Position
Kevin Tang	Chief Executive Officer
Michael Hearne	Chief Financial Officer
Ryan Cole	Chief Operating Officer